TABLE 3

Correlation Between SUVmax and Disease-Free Survival

	Whole cohort		Men		Women
Factor	HR	P	HR	P	HR	P
Pairwise analysis^*
Age	1.85 (1.23–2.80)	0.003	2.93 (1.79–4.80)	<0.001	0.70 (0.31–1.61)	0.401
Sex	1.99 (1.31–3.00)	0.001	Not applicable		Not applicable
ECOG	1.67 (1.10–2.54)	0.016	2.64 (1.61–4.32)	<0.001	0.60 (0.26–1.39)	0.234
Histology	1.70 (1.12–2.57)	0.012	2.47 (1.49–4.09)	<0.001	0.68 (0.30–1.55)	0.357
Grade	1.64 (1.07–2.52)	0.023	2.69 (1.63–4.44)	<0.001	0.50 (0.20–1.26)	0.143
Pathologic TNM stage	1.42 (0.92–2.19)	0.109	2.45 (1.40–4.26)	0.002	0.60 (0.26–1.39)	0.233
Diameter	1.57 (1.00–2.47)	0.05	2.76 (1.60–4.75)	<0.001	0.52 (0.21–1.28)	0.155
Vascular invasion	1.70 (1.12–2.59)	0.013	2.77 (1.69–4.56)	<0.001	0.50 (0.21–1.20)	0.119
Lymphatic invasion	1.65 (1.09–2.52)	0.019	2.77 (1.69–4.55)	<0.001	0.46 (0.19–1.09)	0.079
Neural invasion	1.76 (1.16–2.66)	0.008	2.78 (1.70–4.55)	<0.001	0.58 (0.25–1.37)	0.216
Diabetes	1.84 (1.21–2.77)	0.004	2.85 (1.75–4.66)	<0.001	0.66 (0.28–1.55)	0.339
Multivariate analysis^†	1.28 (0.79–2.08)	0.318	1.96 (1.08–3.58)	0.027	0.47 (0.14–1.56	0.22

↵* Correlation between SUVmax and survival, controlling for all prognostic factors.
↵† Correlation between SUVmax and survival, controlling for all prognostic factors.
Data in parentheses are 95% CIs.